Blood glucose fluctuation accelerates renal injury involved to inhibit the AKT signaling pathway in diabetic rats

Endocrine ◽  
2016 ◽  
Vol 53 (1) ◽  
pp. 81-96 ◽  
Author(s):  
Changjiang Ying ◽  
Xiaoyan Zhou ◽  
Zhenzhen Chang ◽  
Hongwei Ling ◽  
Xingbo Cheng ◽  
...  
2019 ◽  
Vol 19 (5) ◽  
pp. 622-631 ◽  
Author(s):  
Ya Liu ◽  
Jian Kang ◽  
Hong Gao ◽  
Xiyu Zhang ◽  
Jun Chao ◽  
...  

Background: Type 2 Diabetes Mellitus (T2DM) is a world-wide metabolic disease with no cure from drugs and treatment. In China, The Traditional Chinese Medicine (TCM) herbal formulations have been used to treat T2DM for centuries. Methods: In this study, we proposed a formula called ShenQi Compound (SQC), which has been used in clinical therapeutics in China for several years. We evaluated the effect of SQC in a spontaneous diabetic rat model (GK rats) by detecting a series of blood indicators and performing histological observations. Meanwhile, the gene microarray and RT-qPCR experiments were used to explore the molecular mechanism of SQC treatment. In addition, western medicine, sitagliptin was employed as a comparison. Results: The results indicated that SQC and sitagliptin could effectively improve the serum lipid (blood Total Cholesterol (TC) and blood Triglycerides (TG)), hormone levels (serum insulin (INS), Glucagon (GC) and Glucagon-Like Peptide-1 (GLP-1)), alleviated the inflammatory response (hypersensitive C-Reactive Protein (hsCRP)), blood glucose fluctuation (Mean Blood Glucose (MBG), standard deviation of blood glucose (SDBG) and Largest Amplitude of plasma Glucose Excursions (LAGE)), pancreatic tissue damage and vascular injury for T2DM. Compared with sitagliptin, SQC achieved a better effect on blood glucose fluctuation (p<0.01). Meanwhile, the gene microarray and RT-qPCR experiments indicated that SQC and sitagliptin may improve the T2DM through affecting the biological functions related to apoptosis and circadian rhythm. Moreover, SQC might be able to influence the mTOR signaling pathway by regulating Pik3r1, Ddit4 expression. Conclusion: All these results indicate that SQC is an effective therapeutic drug on T2DM. Notably, SQC presents an obvious blood glucose fluctuation-preventing ability, which might be derived from the regulation of the mTOR signaling pathway.


2020 ◽  
Author(s):  
Dongsheng Xu ◽  
Wenjun Li ◽  
Tao Zhang ◽  
Gang Wang

Abstract Background To investigate the effect of miR-10a on PI3K/AKT signaling pathway. The ischemia-reperfusion injury models of rats were simulated in vivo . Methods RT-PCR was used to test the expression of miR-10a. The serum creatinine and urea nitrogen levels were determined. The pathological changes and the apoptosis of renal cells were observed. The model of HK-2 cells with hypoxia-reoxygenation was established in vitro. The cell proliferation and apoptosis rate were tested by CCK8, clone formation and flow cytometry, respectively. The apoptosis-related proteins and PIK3CA and PI3K/AKT signaling pathway-related proteins were detected by Western blot both in vivo and intro . The dual luciferase assay was used to verify whether PIK3CA is a target gene of miR-10a. PIK3CA gene was over-expression or silenced. The transfection efficiency was verified by RT-PCR and the above experiments were repeated. Results Compared with I/R group, miR-10a RNA was significantly increased in renal tissue of miR-10a group, serum Cr and BUN levels, and renal injury score and apoptosis index were significantly increased, while the expression of PI3K/AKT signaling pathway-related proteins were significantly inhibited. However, the indicators above were contrary in anti-miR group. In comparison with H/R group, miR-10a RNA expression was remarkably increased in miR-10a cells and the cell proliferation was inhibited. The apoptosis rate was increased and the expression of PI3K/AKT signaling pathway-related proteins were down-regulated. However, the indicators above were contrary in anti-miR group. Conclusion miR-10a can aggravate the ischemia-reperfusion-induced renal injury in rats by targeting PIK3CA and inhibitingPI3K/AKT signaling pathway.


PLoS ONE ◽  
2018 ◽  
Vol 13 (10) ◽  
pp. e0205456 ◽  
Author(s):  
Takamasa Tsuzuki ◽  
Toshinori Yoshihara ◽  
Noriko Ichinoseki-Sekine ◽  
Ryo Kakigi ◽  
Yuri Takamine ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document